Targeting the urokinase plasminogen activator (uPA) pathway inhibits pancreatic cancer progression

Pancreatology ◽  
2021 ◽  
Vol 21 ◽  
pp. S73
Author(s):  
S.M.Z. Hosen ◽  
J. Haar ◽  
Z. Xu ◽  
C. Perera ◽  
B.J. Buckley ◽  
...  
2020 ◽  
Vol 5 (2) ◽  
pp. 171
Author(s):  
Tungki Pratama Umar ◽  
Muhammad Syahrul Ramadhan ◽  
Nindya Mahfuza

Pancreatic cancer is the cancer with highest mortality-incidence rate compared with other types of cancer. Most cases can only be treated palliatively. Targeted therapy comes as an alternative to its treatment especially with Switchable CAR T-cells (sCAR T-cells). In pancreatic cancer, urokinase plasminogen activator receptor (uPAR) is a specific target that is excessively expressed in tumor cell microenvironment. Targeted therapy using sCAR T-cells has been proved safe and effective in other types of malignancy such as B cell lymphoma, so it has potency as immunotherapy agent in pancreatic cancer patient.International Journal of Human and Health Sciences Vol. 05 No. 02 April’21 Page: 171-176


2013 ◽  
Vol 24 (17) ◽  
pp. 2620-2632 ◽  
Author(s):  
Swapna Asuthkar ◽  
Victoria Stepanova ◽  
Tatiana Lebedeva ◽  
AiXuan L. Holterman ◽  
Norman Estes ◽  
...  

Pancreatic ductal adenocarcinoma (PDAC) is almost always lethal. One of the underlying reasons for this lethality is believed to be the presence of cancer stem cells (CSC), which impart chemoresistance and promote recurrence, but the mechanisms responsible are unclear. Recently the poor prognosis of PDAC has been correlated with increased expression of urokinase plasminogen activator (uPA). In the present study we examine the role of uPA in the generation of PDAC CSC. We observe a subset of cells identifiable as a side population (SP) when sorted by flow cytometry of MIA PaCa-2 and PANC-1 pancreatic cancer cells that possess the properties of CSC. A large fraction of these SP cells are CD44 and CD24 positive, are gemcitabine resistant, possess sphere-forming ability, and exhibit increased tumorigenicity, known characteristics of cancer stemness. Increased tumorigenicity and gemcitabine resistance decrease after suppression of uPA. We observe that uPA interacts directly with transcription factors LIM homeobox-2 (Lhx2), homeobox transcription factor A5 (HOXA5), and Hey to possibly promote cancer stemness. uPA regulates Lhx2 expression by suppressing expression of miR-124 and p53 expression by repressing its promoter by inactivating HOXA5. These results demonstrate that regulation of gene transcription by uPA contributes to cancer stemness and clinical lethality.


2017 ◽  
Vol 12 ◽  
pp. 117727191771544 ◽  
Author(s):  
Susanna WL de Geus ◽  
Victor M Baart ◽  
Martin C Boonstra ◽  
Peter JK Kuppen ◽  
Hendrica AJM Prevoo ◽  
...  

The urokinase plasminogen activator receptor (uPAR) has been proposed as a potential prognostic factor for various malignancies. The aim of this study is to assess the prognostic value of uPAR expression in neoplastic and stromal cells of patients with pancreatic adenocarcinoma. Urokinase plasminogen activator receptor expression was determined by immunohistochemistry in 122 pancreatic ductal adenocarcinomas. Kaplan-Meier and Cox regression analyses were used to determine the association with survival. Respectively 66%, 82% and 62% of patients with pancreatic cancer expressed uPAR in neoplastic cells, stromal, and in both combined. Multivariate analysis showed a significant inverse association between uPAR expression in both neoplastic and stromal cells and overall survival. The prognostic impact of uPAR in stromal cells is substantial, but not as pronounced as that of uPAR expression in neoplastic cells. This study suggests a role for uPAR as a biomarker to single out higher risk subgroups of patients with pancreatic cancer.


Sign in / Sign up

Export Citation Format

Share Document